Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacillus coagulans IBRC-M10791
- Development stage
- Preclinical
- Lead developer
- Iranian Biological Resource Center
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bacillus coagulans IBRC-M10791 is a novel probiotic strain investigated for its potential therapeutic application in multiple sclerosis (MS). Research in cuprizone-induced mouse models of demyelination indicates that the strain can modulate the gut microbiota and metabolome, leading to a significant reduction in pro-inflammatory cytokines such as IL-17 and IFN-gamma, while modulating anti-inflammatory factors like IL-4 and TGF-beta. Furthermore, it downregulates the expression of key genes in the tryptophan (IDO-1), vitamin D (CYP27B1), and inflammasome (NLRP1, NLRP3, AIM2) pathways. These molecular changes are associated with enhanced remyelination and improved cognitive performance, suggesting its potential as a co-therapeutic strategy for neurodegenerative and inflammatory diseases.
- Other names
- Bacillus coagulans IBRC-M10791
02
Targets
CYP27B1 (Cytochrome P450 27B1)AIM2 (Absent in melanoma 2)IFNG (Interferon gamma)IL-17A (Interleukin-17A)IDO1 (Indoleamine 2,3-dioxygenase 1)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on bacillus coagulans IBRC-M10791.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacillus coagulans IBRC-M10791.